• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alphaeon enters agreement with PhysIOL for trifocal lens technology

Article

Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.

Las Vegas-Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.

Specific terms of the agreement were not disclosed in a statement from the company.

PhysIOL’s research and development has produced a range of innovative products, designed in partnership with ophthalmic surgeons, as well as specialized research centers and universities. This partnership enables Alphaeon to bring PhysIOL trifocal lens technology to the United States for the first time, according to the statement.

 

“Alphaeon’s development and regulatory capabilities combined with our expertise in design and manufacturing of trifocal IOL technologies make this an ideal partnership,” said Marc Nolet, chief executive officer (CEO) of PhysIOL. “Additionally, we’re excited to leverage Alphaeon’s market access through its highly innovative ShoutMD proprietary social commerce platform.”

“We are very pleased to collaborate with PhysIOL,” said Robert E. Grant, CEO of Alphaeon. “With this new agreement, we will seek to advance the premium category for patients looking for excellent visual acuity outcomes across their range of vision, at near, mid, and distance.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.